Cover Image
Market Research Report

Global Ophthalmic Drugs Market Forecast 2017-2024

Published by Inkwood Research Product code 444523
Published Content info 165 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Ophthalmic Drugs Market Forecast 2017-2024
Published: February 15, 2017 Content info: 165 Pages
Description

KEYFINDINGS

The global ophthalmic drugs market is estimated to grow at an approximate CAGR of 7.86% during the period of 2017 and 2024. An existing predominance and increase in the number of eye disorders with growing geriatric population all over the world are the primary drivers responsible for the market growth. With increasing awareness of ophthalmic drugs among the consumers and patients is anticipated to proliferate the market growth.

MARKET INSIGHTS

The ophthalmic drugs market is segmented on the basis of End-user, Prescription type, and Geography. The Prescription type ophthalmic drugs market is segregated into Prescription Market for Ophthalmic Drugs and OTC (Over the Counter Drugs) Market for Ophthalmic Drugs. The End-user ophthalmic drugs market is segregated into Hospitals, Eye Clinics, Diagnostic Centers, and Patients. The ophthalmic drugs market on the basis of Geography is segregated into Asia-Pacific, Europe, North America, Middle East & Africa and Central & South America.

The technological advancements, rise in eye disorders, growth in geriatric population, cataract surgeries and upsurge in healthcare expenditure are dominant drivers for the growth of ophthalmic drugs market. A vast scope for ophthalmic drugs market is created with the predominance of eye-related disorders and ailments. One major cause for half-blindness and decreased vision is Cataract with the highest percentage accountable of worldwide visual impairment. Cataract surgery is risk-free and secure kind of surgery; the safety has led to an increase in the cataract surgeries. The boost in Health expenditure has boosted the consumer spending indirectly driving the ophthalmic drugs market.

REGIONAL INSIGHTS

North America accounts for the largest market share in the global ophthalmic drugs market. Europe accounts for a second largest market share in the global ophthalmic drugs market. Asia-Pacific is estimated to expand at the highest CAGR during the forecast period. Asia-Pacific is also anticipated to emerge as a leading destination for drug development during the forecast years. The rise in aged population and existence of dominant market players in the regions are driving the regional markets. The Middle East & Africa and Central & South America ophthalmic drugs market are projected to expand during the forecast years with the rise in aged population and predominance of eye ailments amongst the population.

COMPETITIVE INSIGHTS

The predominant ophthalmic drugs companies in the global market are Bayer, Akorn, Johnson and Johnson, Abbott Laboratories, Valeant, Allergan Inc., Regeneron, Merck & Co., Pfizer Inc., Lpath Incorporated, Novartis Ag, Roche Holding Ag, Eyegate Pharmaceuticals, GlaxoSmithKline, Santen Pharmaceutical Co. Ltd, Sun Pharmaceuticals Industries, Ltd., Senju Pharmaceutical Co., Ltd, Cipla Pharmaceuticals and EyeMed.

Table of Contents
Product Code: 2970

TABLE OF CONTENTS

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET OVERVIEW

4. MARKET DETERMINANTS

  • 4.1. MARKET DRIVERS
    • 4.1.1. INCREASING GERIATRIC POPULATION GLOBALLY
    • 4.1.2. TECHNOLOGICAL ADVANCEMENT
    • 4.1.3. RISING PREVALENCE OF EYE DISORDERS
    • 4.1.4. INCREASED HEALTHCARE EXPENDITURE
    • 4.1.5. CATARACT SURGERIES ON RISE
  • 4.2. MARKET RESTRAINTS
    • 4.2.1. RENOWNED DRUGS GOING OFF-PATENT
    • 4.2.2. DELAY IN DRUGS APPROVALS
  • 4.3. MARKET OPPORTUNITIES
    • 4.3.1. INCREASE IN DISORDER SYMPTOM AWARENESS LEADING TO HIGHER TREATMENT RATES
    • 4.3.2. GROWING OPPORTUNITIES IN DEVELOPING ECONOMIES

5. GLOBAL OPHTHALMIC DRUGS MARKET BY PRESCRIPTION TYPE

  • 5.1. GLOBAL PRESCRIPTION MARKET FOR OPHTHALMIC DRUGS
  • 5.2. GLOBAL OTC (OVER THE COUNTER DRUGS) MARKET FOR OPHTHALMIC DRUGS

6. GLOBAL OPHTHALMIC DRUGS MARKET BY END USER

  • 6.1. GLOBAL HOSPITALS OPHTHALMIC DRUGS MARKET
  • 6.2. GLOBAL EYE CLINICS OPHTHALMIC DRUGS MARKET
  • 6.3. GLOBAL DIAGNOSTIC CENTERS OPHTHALMIC DRUGS MARKET
  • 6.4. GLOBAL PATIENTS OPHTHALMIC DRUGS MARKET

7. KEY ANALYTICS

  • 7.1. VALUE CHAIN ANALYSIS
    • 7.1.1. RESEARCH AND DEVELOPMENT
    • 7.1.2. MANUFACTURING
    • 7.1.3. MARKETING AND DISTRIBUTION
  • 7.2. PORTER'S FIVE FORCES ANALYSIS
    • 7.2.1. BARGAINING POWER BUYERS
    • 7.2.2. BARGAINING POWER OF SUPPLIER
    • 7.2.3. THREATS OF NEW ENTRANTS
    • 7.2.4. THREATS OF SUBSTITUTES
    • 7.2.5. COMPETITIVE RIVALRY
  • 7.3. SEE-SAW ANALYSIS

8. REGIONAL ANALYSIS

  • 8.1. NORTH AMERICA
    • 8.1.1. UNITED STATES (U.S.)
    • 8.1.2. CANADA
    • 8.1.3. MEXICO
  • 8.2. EUROPE
    • 8.2.1. GERMANY
    • 8.2.2. UNITED KINGDOM (UK)
    • 8.2.3. RUSSIA
    • 8.2.4. FRANCE
    • 8.2.5. ITALY
    • 8.2.6. SPAIN
  • 8.3. ASIA PACIFIC
    • 8.3.1. CHINA
    • 8.3.2. INDIA
    • 8.3.3. SOUTH KOREA
    • 8.3.4. JAPAN
    • 8.3.5. AUSTRALIA
  • 8.4. MIDDLE EAST & AFRICA
  • 8.5. CENTRAL &SOUTH AMERICA

9. COMPETITIVE LANDSCAPE

  • 9.1. ABBOTT LABORATORIES
  • 9.2. ALLERGAN INC.
  • 9.3. JOHNSON AND JOHNSON
  • 9.4. BAYER
  • 9.5. VALEANT
  • 9.6. REGENERON
  • 9.7. AKORN
  • 9.8. EYEMED
  • 9.9. SENJU PHARMACEUTICAL CO., LTD
  • 9.10. PFIZER INC.
  • 9.11. MERCK & CO.
  • 9.12. NOVARTIS AG
  • 9.13. GLAXOSMITHKLINE
  • 9.14. EYEGATE PHARMACEUTICALS
  • 9.15. LPATH INCORPORATED
  • 9.16. ROCHE HOLDING AG
  • 9.17. SANTEN PHARMACEUTICAL CO. LTD
  • 9.18. CIPLA PHARMACEUTICALS
  • 9.19. SUN PHARMACEUTICALS INDUSTRIES, LTD.

LIST OF TABLES

  • TABLE#1: GLOBAL OPHTHALMIC DRUGS MARKET REVENUE BY GEOGRAPHY 2017-2024($ MILLION)
  • TABLE#2: COMMON CAUSES OF LOSS OF VISION IN THE ELDERLY
  • TABLE#3: EYE DRUGS GONE OFF-PATENT OFF
  • TABLE#4: GLOBAL OPHTHALMIC DRUGS MARKET BY PRESCRIPTION TYPE 2017 - 2024 ($ MILLION)
  • TABLE#5: RECENT FDA APPROVED DRUGS FOR OPHTHALMOLOGY
  • TABLE#6: DETAILS OF SOME KEY PRESCRIPTION DRUGS
  • TABLE#7: OPHTHALMIC DRUGS PRODUCTS FOR OVER-THE-COUNTER HUMAN USE
  • TABLE#8: GLOBAL OPHTHALMIC DRUGS MARKET BY END USER 2017 - 2024 ($ MILLION)
  • TABLE#9: NORTH AMERICA MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
  • TABLE#10: NORTH AMERICA MARKET ESTIMATES AND FORECAST BY REGION 2017-2024 ($ MILLION)
  • TABLE#11: U.S. MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
  • TABLE#12: U.S. HOSPITAL FACT SHEET, 2016
  • TABLE#13: CANADA MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
  • TABLE#14: MEXICO MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
  • TABLE#15: EUROPE MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
  • TABLE#16: EXTRAPOLATION OF PREVALENCE RATE OF GLAUCOMA BY COUNTRIES
  • TABLE#17: EUROPE MARKET ESTIMATES AND FORECAST BY REGION 2017-2024 ($ MILLION)
  • TABLE#18: GERMANY MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024($ MILLION)
  • TABLE#19: UK MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
  • TABLE#20: RUSSIA MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
  • TABLE#21: NUMBER OF HOSPITALS IN RUSSIAN COUNTRIES, 2015
  • TABLE#22: FRANCE MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
  • TABLE#23: FRANCE MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
  • TABLE#24: ITALY MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
  • TABLE#25: SPAIN MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
  • TABLE#26: ASIA-PACIFIC MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
  • TABLE#27: ASIA-PACIFIC MARKET ESTIMATES AND FORECAST BY REGION 2017-2024 ($ MILLION)
  • TABLE#28: PREVALENCE RATE OF EYE RELATED DISEASES IN CHINA, 2014
  • TABLE#29: CHINA MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
  • TABLE#30: INDIA MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
  • TABLE#31: HUMAN RESOURCE NEEDS FOR EYE CARE IN INDIA
  • TABLE#32: SOUTH KOREA MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
  • TABLE#33: JAPAN MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
  • TABLE#34: AUSTRALIA MARKET ESTIMATES AND FORECAST BY END-USER 2017-2024 ($ MILLION)
  • TABLE#35: MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2017-2024 ($ MILLION)
  • TABLE#36: CENTRAL & SOUTH AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2017-2024 ($ MILLION)

LIST OF FIGURES

  • FIGURE#1: GLOBAL OPHTHALMIC DRUGS MARKET BY GEOGRAPHY 2012 AND 2022 (%)
  • FIGURE#2: GLOBAL OPHTHALMIC DRUGS MARKET BY PRESCRIPTION TYPE 2017-2024 ($ MILLION)
  • FIGURE#3: THE POPULATION OF PEOPLE AGED 65 AND OVER WILL DOUBLE IN THE NEXT 25 YEARS (IN MILLIONS)
  • FIGURE#4: PROJECTIONS FOR THE PROPORTION OF GERIATRIC (60+) POPULATION IN 2015, 2030 & 2050
  • FIGURE#5: WORLDWIDE PREVALENCE OF PRESBYOPIA 2015, 2020 & 2050 (BILLION)
  • FIGURE#6: PREVALENCE OF GLAUCOMA AT GLOBAL LEVEL IN 2013, 2020 & 2040 (MILLION)
  • FIGURE#7: GLOBAL HEALTHCARE EXPENDITURE (% OF GDP) 2012-2014
  • FIGURE#8: HEALTHCARE EXPENDITURE OF DEVELOPED ECONOMIES AS % OF THEIR GDP IN 2014
  • FIGURE#9: HEALTHCARE EXPENDITURE OF DEVELOPING ECONOMIES AS % OF THEIR GDP IN 2014
  • FIGURE#10: OPHTHALMIC DRUGS BY TYPE IN 2016 (%)
  • FIGURE#11: GLOBAL HOSPITALS OPHTHALMIC DRUGS MARKET 2017 - 2024 ($ MILLION)
  • FIGURE#12: TOTAL OPHTHALMIC CARE HOSPITAL IN U.S. 2014
  • FIGURE#13: GLOBAL EYE CLINICS OPHTHALMIC DRUGS MARKET 2017 - 2024 ($ MILLION)
  • FIGURE#14: EYE DISEASES CASES IN MILLION ABOVE AGE OF 40 IN AMERICA 2015
  • FIGURE#15: GLOBAL DIAGNOSTIC CENTERS OPHTHALMIC DRUGS MARKET 2017 - 2024 ($ MILLION)
  • FIGURE#16: TOTAL VISUAL IMPAIRMENT AND BLINDNESS CASES ABOVE AGE 40 IN U.S. IN 2015 (IN MILLION)
  • FIGURE#17: CASES ABOVE AGE 40 IN AMERICA 2014 (MILLION)
  • FIGURE#18: GLOBAL PATIENTS OPHTHALMIC DRUGS MARKET 2017 - 2024 ($ MILLION)
  • FIGURE#19: NORTH AMERICA MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
  • FIGURE#20: U.S. POPULATION AGES 65 AND OLDER, 1960 TO 2060 (MILLION)
  • FIGURE#21: U.S. MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
  • FIGURE#22: CAUSES OF VISUAL IMPAIRMENT IN U.S., 2014
  • FIGURE#23: CANADA MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
  • FIGURE#24: PREVALENCE RATE OF RETINAL DISORDERS IN CANADA, 2014
  • FIGURE#25: FINANCIAL COST SHARE OF RETINA DISORDER TREATMENT IN CANADA
  • FIGURE#26: MEXICO MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
  • FIGURE#27: PERCENTAGE OF PEOPLE AGED 65+, MEXICO (1950-2050)
  • FIGURE#28: PROPORTION OF DIRECT COST OF EYE DISEASE IN MEXICO, BY PAYER
  • FIGURE#29: EUROPE MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
  • FIGURE#30: DEVELOPMENT OF THE EUROPEAN POPULATION AGED 65 AND OVER, 2010, 2025 & 2050 (IN MILLION)
  • FIGURE#31: PROPORTION OF OPTOMETRISTS AND OPTICIANS IN EUROPEAN COUNTRIES 2015
  • FIGURE#32: GERMANY MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
  • FIGURE#33: POPULATION AGES 65 AND ABOVE (% OF TOTAL)
  • FIGURE#34: NUMBER OF LASIK SURGERIES IN GERMANY 2012-2014 (1000S)
  • FIGURE#35: UK MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
  • FIGURE#36: PROJECTED NUMBER OF PEOPLE LIVING WITH SIGHT LOSS IN THE UK (IN MILLION)
  • FIGURE#37: RUSSIA MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
  • FIGURE#38: POPULATION AGES 65 AND ABOVE IN FRANCE (% OF TOTAL)
  • FIGURE#39: POPULATION AGES 65 AND ABOVE IN ITALY (% OF TOTAL)
  • FIGURE#40: ITALY MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
  • FIGURE#41: POPULATION AGES 65 AND ABOVE IN SPAIN (% OF TOTAL)
  • FIGURE#42: SPAIN MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
  • FIGURE#43: ASIA-PACIFIC MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
  • FIGURE#44: CHINA MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
  • FIGURE#45: INDIA MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
  • FIGURE#46: SOUTH KOREA MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
  • FIGURE#47: NUMBER OF YEARS FOR PERCENTAGE AGED 65 AND ABOVE IN TOTAL POPULATION TO TRIPLE
  • FIGURE#48: POPULATION AGES 65 AND ABOVE IN JAPAN (% OF TOTAL)
  • FIGURE#49: JAPAN MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
  • FIGURE#50: POPULATION AGES 65 AND ABOVE IN AUSTRALIA (% OF TOTAL)
  • FIGURE#51: AUSTRALIA MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
  • FIGURE#52: MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
  • FIGURE#53: PATIENTS VISIT DUBAI HEALTHCARE CITY 2014-2015 (IN MILLION)
  • FIGURE#54: CENTRAL & SOUTH AMERICA MARKET ESTIMATES AND FORECAST 2017-2024 ($ MILLION)
  • FIGURE#55: AGING POPULATION GROWTH RATE, 2000-2050
  • FIGURE#56: AGING POPULATION IN COLOMBIA 1950-2050 (IN THOUSANDS)
  • FIGURE#57: GLOBAL OPHTHALMIC DRUGS MARKET SHARE 2016(%)
  • FIGURE#58: ABBOTT LABORATORIES REVENUE 2013-2015 ($ MILLION)
  • FIGURE#59: ALLERGAN INC. REVENUE 2013-2015 ($ MILLION)
  • FIGURE#60: JOHNSON & JOHNSON REVENUE 2013-2015 ($ MILLION)
  • FIGURE#61: BAYER AG REVENUE 2013-2015 ($ MILLION)
  • FIGURE#62: VALEANT PHARMACEUTICALS INTERNATIONAL, INC. REVENUE 2013-2015 ($ MILLION)
  • FIGURE#63: REGENERON PHARMACEUTICALS, INC. REVENUE 2013-2015 ($ MILLION)
  • FIGURE#64: EYEMED VISION CARE REVENUE 2013-2015 ($ MILLION)
  • FIGURE#65: PFIZER INC. REVENUE 2013-2015 ($ MILLION)
  • FIGURE#66: MERCK & CO., INC. REVENUE 2013-2015 ($ MILLION)
  • FIGURE#67: NOVARTIS AG REVENUE 2013-2015 ($ MILLION)
  • FIGURE#68: GLAXOSMITHKLINE REVENUE 2013-2015 ($ MILLION)
  • FIGURE#69: ROCHE HOLDING AG NET SALES 2013-2015 ($ MILLION)
  • FIGURE#70: SANTEN PHARMACEUTICAL CO. LTD NET SALES 2013-2015 ($ MILLION)
  • FIGURE#71: CIPLA LTD. NET SALES 2013-2015 ($ MILLION)
  • FIGURE#72: SUN PHARMACEUTICALS INDUSTRIES LTD. NET SALES 2013-2015 ($ MILLION)
Back to Top